Anzeige
Mehr »
Samstag, 28.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DPH3 | ISIN: US6876041087 | Ticker-Symbol: HQ1
Tradegate
27.06.25 | 16:57
9,550 Euro
+1,06 % +0,100
1-Jahres-Chart
ORUKA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
ORUKA THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
9,2509,65013:03
9,3509,75027.06.

Aktuelle News zur ORUKA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
03.06.Oruka Therapeutics, Inc. - 8-K, Current Report1
27.05.H.C. Wainwright Maintains Buy Rating on Oruka (ORKA) After the Early Start of OKRA-002 Trial2
27.05.H.C. Wainwright maintains Buy on Oruka stock, $45 target1
22.05.BTIG sets $44 price target on Oruka Therapeutics stock1
22.05.BTIG setzt Kursziel von 44 US-Dollar für Oruka Therapeutics-Aktie2
20.05.Oruka Therapeutics startet Studie für Psoriasis-Behandlung1
ORUKA THERAPEUTICS Aktie jetzt für 0€ handeln
20.05.Oruka Therapeutics begins trial for psoriasis treatment1
20.05.Oruka Therapeutics, Inc.: Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody105Pharmacokinetic and safety data from healthy volunteers anticipated around YE 2025 On track to initiate a Phase 2 study in 1H 2026 ORKA-002 preclinical data demonstrate the potential for dosing two...
► Artikel lesen
14.05.Oruka Therapeutics, Inc.: Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update178Continued operational excellence leading to acceleration of multiple timelines: ORKA-001, targeting IL-23p19, Phase 1 trial dosing complete, with data expected in 3Q 2025 ORKA-001 Phase 2a initiation...
► Artikel lesen
14.05.Oruka Therapeutics, Inc. - 10-Q, Quarterly Report1
07.03.Stifel maintains Buy rating on Oruka Therapeutics stock, $49 target1
07.03.Oruka Therapeutics, Inc.: Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting1.833Half-life in non-human primates (NHP) of more than 30 days, over three times longer than bimekizumab and expected to support a dose interval of two to three times per year Equivalent potency to bimekizumab...
► Artikel lesen
06.03.Oruka Therapeutics, Inc. Q4 Loss Narrows1
06.03.ARCA biopharma GAAP EPS of -$0.49 misses by $0.082
06.03.Oruka Therapeutics, Inc.: Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update164ORKA-001, targeting IL-23p19, Phase 1 trial ongoing, with pharmacokinetic (PK) data expected in 2H 2025 ORKA-001 Phase 2a initiation expected in 2H 2025, with efficacy readout in 2H 2026 that provides...
► Artikel lesen
06.03.Oruka Therapeutics, Inc. - 10-K, Annual Report-
05.02.Oruka Therapeutics, Inc. - 8-K, Current Report1
19.12.24Oruka Therapeutics, Inc.: Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody244Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025 On track to initiate a proof-of-concept study in psoriasis in the second half of 2025, with initial efficacy...
► Artikel lesen
18.12.24Oruka Therapeutics, Inc.: Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)199MENLO PARK, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment...
► Artikel lesen
13.11.24Oruka Therapeutics, Inc.: Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update201Successful go-public transaction and over $475 million raised this year provides cash runway through multiple clinical inflection points ORKA-001 non-human primate (NHP) pharmacokinetic and in vitro...
► Artikel lesen
Weiter >>
34 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1